SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-061967
Filing Date
2023-05-18
Accepted
2023-05-17 17:43:56
Documents
13
Period of Report
2023-05-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2316034d1_8k.htm   iXBRL 8-K 29755
2 EXHIBIT 10.1 tm2316034d1_ex10-1.htm EX-10.1 32664
  Complete submission text file 0001104659-23-061967.txt   243756

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA icpt-20230515.xsd EX-101.SCH 3054
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE icpt-20230515_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE icpt-20230515_pre.xml EX-101.PRE 22609
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2316034d1_8k_htm.xml XML 3498
Mailing Address 305 MADISON AVENUE MORRISTOWN NJ 07960
Business Address 305 MADISON AVENUE MORRISTOWN NJ 07960 646-747-1000
INTERCEPT PHARMACEUTICALS, INC. (Filer) CIK: 0001270073 (see all company filings)

IRS No.: 223868459 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35668 | Film No.: 23933086
SIC: 2834 Pharmaceutical Preparations